Dimensional Fund Advisors
RAPP

Dimensional Fund Advisors’s Rapport Therapeutics RAPP Stock Holding History

Dimensional Fund Advisors’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.1M Buy
362,114
+137,616
+61% +$5.06M ﹤0.01% 2154
2026
Q1 		$7.02M Buy
224,498
+141,011
+169% +$3.97M ﹤0.01% 2388
2025
Q4 		$2.53M Buy
83,487
+72,157
+637% +$2M ﹤0.01% 2687
2025
Q3 		$337K Buy
+11,330
New +$202K ﹤0.01% 3056

Other funds holding RAPP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TGV
TRV GP V Boston, Massachusetts $498M AUM 267.53% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Dimensional Fund Advisors's RAPP Position: Q2 2026 in Review

Dimensional Fund Advisors increased its Rapport Therapeutics (RAPP) stake by 61% in Q2 2026, buying an estimated $5.06M and bringing the position to 362,114 shares worth $15.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2154.

Dimensional Fund Advisors first reported a position in RAPP in Q3 2025 and has held it in 4 quarters since. 160 funds tracked by Wall St. Rank hold RAPP as of Q2 2026.

  • Dimensional Fund Advisors held 362,114 shares of Rapport Therapeutics worth $15.1M as of Q2 2026.
  • Dimensional Fund Advisors bought 137,616 Rapport Therapeutics shares in Q2 2026, an estimated $5.06M.
  • Rapport Therapeutics made up ﹤0.01% of Dimensional Fund Advisors's portfolio in Q2 2026, its #2154 holding.
  • Dimensional Fund Advisors first reported a position in Rapport Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 160 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q2 2026.

Based on Dimensional Fund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.